Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Marre, MUSTAFA; SHAW, J.; BRAENDLE, M.; Bebakar, W.; Kamaruddin, N.; STRAND, J.; ZDRAVKOVIC, M.; LE THI, T.; Colagiuri, S.

doi:10.1111/j.1464-5491.2009.02666.x

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Atıf İçin Kopyala

Marre M. K., SHAW J., BRAENDLE M., Bebakar W. M. W., Kamaruddin N. A., STRAND J., ...Daha Fazla

DIABETIC MEDICINE, cilt.26, sa.3, ss.268-278, 2009 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 26 Sayı: 3
Basım Tarihi: 2009
Doi Numarası: 10.1111/j.1464-5491.2009.02666.x
Dergi Adı: DIABETIC MEDICINE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.268-278
Anahtar Kelimeler: dipeptidyl peptidase-4, glucagon-like peptide-1 receptor agonist, incretin, insulinotropic, thiazolidinedione, GLUCAGON-LIKE PEPTIDE-1, BETA-CELL FUNCTION, METFORMIN, SAFETY, HYPERGLYCEMIA, GLIMEPIRIDE, REDUCTION, EXENDIN-4, MELLITUS, EFFICACY
Akdeniz Üniversitesi Adresli: Evet

Özet

To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.